Breakthrough, historic and game changing news showing impressive reductions in the degree of obesity in adolescents aged 12-17 years with once weekly #semaglutide 2.4 mg. We need to have the conversation to provide chronic care #OW2022@novonordisk
Therapeutic options for management of #obesity are limited and often challenging in adolescents. Semaglutide appears to represent a useful strategy to consider for some young people living with and impacted by #obesity#weightloss#OW2022